Sildenafil citrate (
Viagra) is the most widely used pharmacological drug for treating
erectile dysfunction in men. It has potent cardioprotective effects against
ischemia-reperfusion injury via
nitric oxide and opening of mitochondrial
ATP-sensitive K(+) channels. We further investigated the role of
protein kinase C (PKC)-dependent signaling pathway in
sildenafil-induced cardioprotection. Rabbits were treated (orally) with
sildenafil citrate (1.4 mg/kg) 30 min before index
ischemia for 30 min and reperfusion for 3 h. The PKC inhibitor
chelerythrine (5 mg/kg i.v.) was given 5 min before
sildenafil.
Infarct size (% of risk area) reduced from 33.65 +/- 2.17 in the vehicle (saline) group to 15.07 +/- 0.63 in
sildenafil-treated groups, a 45% reduction compared with vehicle (mean +/- SE, P < 0.05).
Chelerythrine abolished
sildenafil-induced protection, as demonstrated by increase in
infarct size to 31.14 +/- 2.4 (P < 0.05).
Chelerythrine alone had an
infarct size of 33.5 +/- 2.5, which was not significantly different compared with
DMSO-treated group (36.8 +/- 1.7, P > 0.05). Western blot analysis demonstrated translocation of PKC-alpha, -, and -delta
isoforms from cytosol to membrane
after treatment with
sildenafil. However, no change in the
PKC-beta and -epsilon
isoforms was observed. These data provide direct evidence of an essential role of PKC, and potentially PKC-alpha, -, and -delta, in
sildenafil-induced cardioprotection in the rabbit heart.